Haiwei Xu received his Ph.D. degree from the Department of Chemistry of Zhengzhou University (China, 2004-2007). He was subsequently appointed as an assistant professor at Zhengzhou University, and thereafter promoted to associate professor in Medicinal Chemistry, School of Pharmaceutical Sciences. His research interest is the discovery and development of novel small-molecule therapeutics based on the natural products. In 2019 he was appointed as a vice dean of School of Pharmaceutical Sciences at Zhengzhou University. He was a visiting professor at Department of Internal Medicine’s Division of Hematology/Oncology, University of Michigan in 2015-2016. He has published more than 40 peer-reviewed papers and holds 22 patents. An investigational new drug (IND) derived from andrographolide was licensed to Shijiazhuang No4 pharmaceutical Co. Ltd in 2018.
Haiwei Xu received his Ph.D. degree from the Department of Chemistry of Zhengzhou University (China, 2004-2007). He was subsequently appointed as an assistant professor at Zhengzhou University, and thereafter promoted to associate professor in Medicinal Chemistry, School of Pharmaceutical Sciences. His research interest is the discovery and development of novel small-molecule therapeutics based on the natural products. In 2019 he was appointed as a vice dean of School of Pharmaceutical Sciences at Zhengzhou University. He was a visiting professor at Department of Internal Medicine’s Division of Hematology/Oncology, University of Michigan in 2015-2016. He has published more than 40 peer-reviewed papers and holds 22 patents. An investigational new drug (IND) derived from andrographolide was licensed to Shijiazhuang No4 pharmaceutical Co. Ltd in 2018.